Research & Pharma Solutions | 

# Focused Tumor Profiling

# Analysis of Selected Tumor-Relevant Genes

Cancer development is a multifactorial process. It begins with genetic changes that lead to abnormally proliferating cells, causing a tumor to grow. During tumor progression, additional mutations can promote rapid growth, enable replicative immortality, induce angiogenesis, enable immune and growth suppressor evasion, and even permit cell death resistance. Thus, tumors can accumulate a multitude of mutations in different genes during their development and progression, leading to the tumor cell's increased capacity for proliferation, survival, invasion, and metastasis. Mutations in specific tumor-relevant genes can have crucial implications for targeted therapy approaches. Key immune-oncology biomarkers like tumor mutational burden (TMB) or microsatellite instability (MSI) can also provide valuable information for treatment choices. However, even if the optimal therapy is found, tumors can develop resistance mutations against the treatment.

With our Focused Tumor Profiling products, selected tumor-relevant genes in your tumor sample can be analyzed. Our products offer a focused, targeted, and efficient method to identify a patient's best treatment choice, find patients eligible for clinical trials, and monitor a patient's mutation status during therapeutic interventions.

Want to Discover More?

We invite you to take a look at our website.

**www.cegat.com/focused-tumor-profiling**

## Explore our Product Portfolio for Focused Tumor Profiling

| | FTP TUM TN | FTP TUM T | FTP PAT T | FTP FUS T |
|---|---|---|---|---|
| **Species** | Human | | | |
| **Sequencing panel** | Tumor panel (CeGaT GmbH) | | Molecular pathology panel (CeGaT GmbH) | RNA fusion panel (CeGaT GmbH) |
| **Number of analyzed genes** | ~ 780 | | 55 | > 200 |
| **Analysis of tumor and normal tissue** | Yes | No | | |
| **Starting material** | Fresh frozen tissue, FFPE tissue, high molecular weight DNA, or fragmented DNA (FFPE) | | | Isolated RNA |
| **Sequencing platform** | Illumina | | | |
| **Output** | 10 Gb normal tissue<br>10 Gb tumor tissue | 10 Gb tumor tissue | Flexible | |
| **Included deliverables** | Project report, files in FASTQ, BAM, CSV, VCF, JSON, GFF3, and TSV format | | Project report, files in FASTQ, BAM, CSV, VCF, JSON, and TSV format | Project report, files in FASTQ, BAM, and TSV format |

**FTP:** Focused Tumor Profiling

# About Us

CeGaT was founded in 2009 in Tübingen, Germany. Our scientists are specialized in next-generation sequencing (NGS) for genetic diagnostics, and we also provide a variety of sequencing services for research purposes and pharma solutions. Our sequencing service portfolio is complemented by analyses suited for microbiome, immunology, and translational oncology studies.

Our dedicated project management team of scientists and bio-informaticians works closely with you to develop the best strategy to realize your project. Depending on its scope, we select the most suitable library preparation and conditions on our sequencing platforms.

**We would be pleased to provide you with our excellent service. Contact us today to start planning your next project.**

DAkkS Deutsche Akkreditierungsstelle D-PL-13206-01-00

Accredited by DAkkS according to DIN EN ISO/IEC 17025:2018

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

CLIA CERTIFIED ID: 99D2130225


CeGaT GmbH
Research & Pharma Solutions
Paul-Ehrlich-Str. 23
72076 Tübingen
Germany

Phone: +49 707156544-333
Fax: +49 707156544-56
Email: rps@cegat.com
Web: www.cegat.com/rps


2025/04